CoChat

Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients

Open access
Gao, Lijun, Huang, Hong, Zhang, Lu, Zhang, Ningjing, Fu, Yuzhe, Zhu, Dalong, Bi, Yan, Feng, Wenhuan · 2022 · Experimental and Clinical Endocrinology & Diabetes

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Purpose We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic. Patients and Methods Seventy-eight non-diabetic patients were randomly selected and beinaglutide or metformin was administered for 12 weeks. The primary endpoints were changes in body weight and the proportions of patients who lost≥5 and≥10% of their baseline body weights. Results A total of 64 patients completed the study; patients in the beinaglutide group exhibited more bodyweight loss than those in the metformin group [(9.5±0.8%; 9.1±0.9 kg) and (5.1±0.9%; 4.5±0.8 kg), respectively, corresponding to a difference of approximately 4.5 kg (95% confidence interval, 2.2–6.9 kg; P<0.01)]. In the beinaglutide group, 90.6 and 40.6% of the patients lost≥5 and≥10% of their body weight, respectively, whereas, in the metformin group, these rates were 46.9 and 12.5%, respectively (P<0.01 and P<0.05). Weight loss following beinaglutide treatment mainly resulted from the loss of fat mass. Compared to metformin, beinaglutide induced a greater decrease in the body mass index, weight circumference, percent body fat, and body fat mass (total, trunk, limb, android, and gynoid). Additionally, beinaglutide decreased serum insulin levels and ameliorated insulin resistance. Conclusions Beinaglutide is more efficient than metformin at reducing weight and fat mass in patients who are overweight/obese and non-diabetic. Beinaglutide may be a useful therapeutic option for overweight/obesity control in the Chinese population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/a-1608-0345

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A flow chart of the enrolment of the study subjects.
Fig. 1 A flow chart of the enrolment of the study subjects.CC BY-NC-ND · PubMed Central
Fig. 2 A comparison of changes in body weight ( a ), body weight ( b ), percentage weight loss ( c ), proportion of patients who lost at least 0, 5, 10, and 15% of their initial body weight ( d ), changes in BMI ( e ), and BMI ( f ) during 12 weeks of treatment between beinaglutide or metformin groups (* P <0.05, ** P <0.01). a, c, d, and e ** P <0.001 * P <0.05; b and f ** P <0.001 * P <0.05 follow-up points vs. baseline. †† P< 0.001 † P <0.05 follow-up points vs. 4 weeks. ‡ P <0.05 follow-up points vs. 8 weeks. BMI, body mass index. .
Fig. 2 A comparison of changes in body weight ( a ), body weight ( b ), percentage weight loss ( c ), proportion of patients who lost at least 0, 5, 10, and 15% of their initial body weight ( d ), changes in BMI ( e ), and BMI ( f ) during 12 weeks of treatment between beinaglutide or metformin groups (* P <0.05, ** P <0.01). a, c, d, and e ** P <0.001 * P <0.05; b and f ** P <0.001 * P <0.05 follow-up points vs. baseline. †† P< 0.001 † P <0.05 follow-up points vs. 4 weeks. ‡ P <0.05 follow-up points vs. 8 weeks. BMI, body mass index. .CC BY-NC-ND · PubMed Central
Fig. 3 Changes in fat mass and lean tissue mass in the same region after treatment with beinaglutide or metformin (* P <0.05,** P <0.01).
Fig. 3 Changes in fat mass and lean tissue mass in the same region after treatment with beinaglutide or metformin (* P <0.05,** P <0.01).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 2

  1. C D Society, 2021, Chinese guideline for the prevention and treatment of type 2 diabetes mellitus (2020 edition), Chin J Endo Metab, 37, 311
  2. 2019, Guideline for primary care of obesity:practice version, Chin J Gen Pract, 2020, 102

Cited by

See all 24

Metadata

Authors
Gao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W.
Affiliations
Nanjing Drum Tower Hospital (CN)
Venue
Experimental and Clinical Endocrinology & Diabetes
Published
2021-12-02
Volume
130
Issue
06
Pages
358-367
ISSN
  • 0947-7349 (ISSN-L)
  • 1439-3646
OpenAlex
W3216965998
Cited by
24
References
34
Citations by year
2026: 5 · 2025: 8 · 2024: 5 · 2023: 6
FWCI
1.61
Type
journal article
Language
en
Open access
Locations
  • Experimental and Clinical Endocrinology & Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81970704, 81970689, 81900787, 81800752, 81800719)
  • National Key Research and Development Program of China (2016YFC1304804, 2017YFC1309605)
  • Jiangsu Provincial Key Medical Discipline (ZDXKB2016012)
  • Key Project of Nanjing Clinical Medical Science, Key Research and Development Program of Jiangsu Province of China (BE2015604, BE2016606)
  • Medical and Health Research Projects of Nanjing in Jiangsu Province of China (YKK18067)
  • Project of Standardised Diagnosis and Treatment of Key Diseases in Jiangsu Province of China (2015604)
  • Natural Science Foundation of Jiangsu Province of China (BK20201115)
  • Drum Tower Hospital
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
metformin, weight loss, obesity, overweight, non-diabetic patients, GLP-1 receptor agonists, insulin resistance, insulin levels, fat mass, body composition, body mass index
MeSH terms
Body Weight, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Obesity, Peptide Fragments, Weight Loss, Overweight, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. https://app.cochat.ai/papers/10.1055/a-1608-0345
The paper
Gao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W. (2022). Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. Experimental and Clinical Endocrinology & Diabetes. https://doi.org/10.1055/a-1608-0345

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.